Cargando…

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study

BACKGROUND: Despite high HIV co-infection prevalence in Ethiopian visceral leishmaniasis (VL) patients, the adequacy of antileishmanial drug exposure in this population and effect of HIV-VL co-morbidity on pharmacokinetics of antileishmanial and antiretroviral (ARV) drugs is still unknown. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kip, Anke E, Blesson, Séverine, Alves, Fabiana, Wasunna, Monique, Kimutai, Robert, Menza, Peninah, Mengesha, Bewketu, Beijnen, Jos H, Hailu, Asrat, Diro, Ermias, Dorlo, Thomas P C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050768/ https://www.ncbi.nlm.nih.gov/pubmed/33677546 http://dx.doi.org/10.1093/jac/dkab013

Ejemplares similares

Impact of the Use of a Rapid Diagnostic Test for Visceral Leishmaniasis on Clinical Practice in Ethiopia: A Retrospective Study
por: Diro, Ermias, et al.
Publicado: (2015)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV
por: Adriaensen, Wim, et al.
Publicado: (2020)

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Visceral Leishmaniasis and HIV Coinfection in East Africa
por: Diro, Ermias, et al.
Publicado: (2014)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
por: Kip, Anke E., et al.
Publicado: (2018)

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection
por: Kip, A. E., et al.
Publicado: (2016)

Prevalence of malnutrition and associated risk factors among adult visceral leishmaniasis patients in Northwest Ethiopia: a cross sectional study
por: Mengesha, Bewketu, et al.
Publicado: (2014)

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
por: Kip, Anke E., et al.
Publicado: (2017)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Visceral Leishmaniasis: New Health Tools Are Needed
por: Hailu, Asrat, et al.
Publicado: (2005)

Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2016)

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
por: Verrest, Luka, et al.
Publicado: (2021)

Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 Production
por: Adem, Emebet, et al.
Publicado: (2016)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

High Parasitological Failure Rate of Visceral Leishmaniasis to Sodium Stibogluconate among HIV Co-infected Adults in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2014)

Serum Levels of Soluble CD40 Ligand and Neopterin in HIV Coinfected Asymptomatic and Symptomatic Visceral Leishmaniasis Patients
por: Adriaensen, Wim, et al.
Publicado: (2018)

Case Report: Atypical Presentation of Visceral Leishmaniasis: Two Cases from Northwest Ethiopia
por: Mohammed, Rezika, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial
por: Mbui, Jane, et al.
Publicado: (2019)

Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector Functions
por: Yizengaw, Endalew, et al.
Publicado: (2016)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Acute kidney injury in patients with Visceral Leishmaniasis in Northwest Ethiopia
por: Hailu, Workagegnehu, et al.
Publicado: (2021)

Leishmania Antigenuria to Predict Initial Treatment Failure and Relapse in Visceral Leishmaniasis/HIV Coinfected Patients: An Exploratory Study Nested Within a Clinical Trial in Ethiopia
por: van Griensven, Johan, et al.
Publicado: (2018)

A Screen-and-Treat Strategy Targeting Visceral Leishmaniasis in HIV-Infected Individuals in Endemic East African Countries: The Way Forward?
por: van Griensven, Johan, et al.
Publicado: (2014)

Inference of Population Structure of Leishmania donovani Strains Isolated from Different Ethiopian Visceral Leishmaniasis Endemic Areas
por: Gelanew, Tesfaye, et al.
Publicado: (2010)

Antigen Detection in Urine for Noninvasive Diagnosis and Treatment Monitoring of Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients: An Exploratory Analysis from Ethiopia
por: Vogt, Florian, et al.
Publicado: (2018)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
por: Verrest, Luka, et al.
Publicado: (2021)

Shigella Bacteremia in a Patient with Visceral Leishmaniasis
por: Endris, Mengistu, et al.
Publicado: (2013)

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
por: Mondal, Dinesh, et al.
Publicado: (2019)

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
por: Khalil, Eltahir A. G., et al.
Publicado: (2014)

A fine scale eco-epidemiological study on endemic visceral leishmaniasis in north ethiopian villages
por: Kirstein, Oscar David, et al.
Publicado: (2018)

Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review
por: van Griensven, Johan, et al.
Publicado: (2016)

Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia
por: Boodman, Carl, et al.
Publicado: (2023)

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
por: Wasunna, Monique, et al.
Publicado: (2016)

Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection
por: Takele, Yegnasew, et al.
Publicado: (2013)

Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines
por: van Griensven, Johan, et al.
Publicado: (2014)

Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites
por: Tajebe, Fitsumbrhan, et al.
Publicado: (2017)

Correction: Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection
por: Takele, Yegnasew, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2fpor4alb5j36o811qfcgvgs40